---
title: "Melanotan-2"
slug: "melanotan-2"
type: "compound"
category: "Sexual Wellness"
url: "https://peptidesciencethailand.com/compounds/melanotan-2"
description: "A melanocortin receptor agonist studied for skin pigmentation and related pathways. Mechanism overview, research findings, and safety considerations."
---
# Melanotan-2

*Synthetic Alpha-MSH Analog, Modulating Melanocortin Receptor Signaling*

**Category:** Sexual Wellness  
**Format:** Lyophilized Vial  
**Amount:** 10mg  
**Purity:** >99% (HPLC)

## Overview

Melanotan-2 (MT-2) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH) with the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. Originally developed at the University of Arizona in the late 1980s by Dr. Victor Hruby and colleagues, the compound was designed as a superpotent, metabolically stable analog of the naturally occurring alpha-MSH peptide. Its cyclic structure confers significant resistance to enzymatic degradation compared to linear melanocortin peptides, resulting in a substantially longer biological half-life and enhanced receptor binding affinity.

At the molecular level, Melanotan-2 functions as a non-selective agonist of melanocortin receptors, a family of five G-protein coupled receptors (MC1R through MC5R) that mediate diverse physiological processes throughout the body. Its primary pharmacological activity centers on activation of MC1R and MC4R subtypes. MC1R activation in melanocytes stimulates eumelanin synthesis through the cyclic adenosine monophosphate (cAMP) signaling cascade, leading to upregulation of tyrosinase and related melanogenic enzymes. This increased eumelanin production results in progressive darkening of skin pigmentation independent of ultraviolet radiation exposure.

MC4R activation in the hypothalamus and other central nervous system structures represents the mechanism underlying Melanotan-2's effects on sexual function pathways. The MC4R is expressed in the paraventricular nucleus (PVN) of the hypothalamus and in spinal cord autonomic centers that regulate erectile function and sexual arousal. Activation of MC4R stimulates downstream signaling through oxytocin-releasing neurons in the PVN, which project to sacral spinal cord segments controlling genital reflexes. This central mechanism of action distinguishes melanocortin-based compounds from peripherally acting agents such as phosphodiesterase-5 inhibitors.

Research published in the International Journal of Impotence Research and other peer-reviewed journals has documented Melanotan-2's ability to initiate erectile responses in both animal models and early-phase human studies. A landmark study by Wessells et al. (1998) demonstrated that subcutaneous administration of Melanotan-2 produced clinically significant erectile responses in men with erectile dysfunction, with effects mediated centrally rather than through peripheral vasodilation. Subsequent research confirmed these findings and extended observations to include effects on female sexual arousal through similar melanocortin-dependent pathways.

Beyond its melanocortin receptor activity, Melanotan-2 interacts with several additional signaling systems relevant to metabolic function. MC3R and MC4R activation in hypothalamic feeding centers modulates appetite and energy expenditure through leptin-melanocortin pathway interactions. Preclinical studies have documented reductions in food intake and body fat accumulation in animal models receiving chronic Melanotan-2 administration, effects attributed to central anorectic signaling through the arcuate nucleus and ventromedial hypothalamus.

The pharmacokinetics of Melanotan-2 following subcutaneous injection demonstrate rapid absorption with peak plasma concentrations achieved within 30 to 60 minutes. The cyclic peptide structure confers an elimination half-life of approximately 1 to 2 hours, though the biological effects on melanogenesis persist substantially longer due to the time required for melanin synthesis and keratinocyte turnover cycles. Pigmentation changes typically become apparent after multiple administrations over days to weeks, reflecting the gradual accumulation of eumelanin in the epidermis.

Safety research has identified several pharmacological effects that require careful medical consideration. Melanotan-2's non-selective melanocortin receptor activation means it simultaneously affects pigmentation, appetite, cardiovascular parameters, and central nervous system function. Nausea, facial flushing, and fatigue represent commonly reported acute effects in clinical studies, attributed to MC3R and MC4R activation in brainstem emetic centers and cardiovascular regulatory nuclei. The compound's effects on melanocyte proliferation and melanin production necessitate thorough dermatological assessment, as stimulation of melanocytic activity in individuals with pre-existing melanocytic nevi requires careful monitoring.

Current research continues to explore more selective melanocortin receptor agonists that retain the desirable MC1R or MC4R activity while minimizing off-target receptor activation. Bremelanotide (PT-141), a related compound derived from Melanotan-2 research, represents one such development, having been approved by the FDA for treatment of hypoactive sexual desire disorder in premenopausal women based on its preferential MC4R activity.

The extensive body of preclinical and early clinical research on Melanotan-2 has provided fundamental insights into melanocortin physiology and the interconnected neural circuits governing pigmentation, sexual function, and energy homeostasis. These findings continue to inform the development of next-generation melanocortin-targeted therapeutics across multiple medical disciplines.

## Mechanism of Action

### Step 1: Melanocortin Receptor Binding

Melanotan-2 binds as a non-selective agonist to melanocortin receptors (MC1R through MC5R), with highest affinity for MC1R in melanocytes and MC4R in hypothalamic neurons, initiating G-protein coupled receptor signaling cascades.

### Step 2: cAMP Cascade Activation

Receptor binding activates adenylyl cyclase through Gs-protein coupling, increasing intracellular cyclic AMP (cAMP) concentrations. Elevated cAMP activates protein kinase A (PKA), which phosphorylates CREB transcription factor to drive melanogenic gene expression.

### Step 3: Tyrosinase Upregulation & Melanogenesis

MC1R-mediated PKA activation in melanocytes upregulates tyrosinase, tyrosinase-related protein 1 (TRP-1), and dopachrome tautomerase (TRP-2), the key enzymes catalyzing eumelanin biosynthesis from L-tyrosine through the DOPA intermediate pathway.

### Step 4: Hypothalamic MC4R Signaling

MC4R activation in the paraventricular nucleus of the hypothalamus stimulates oxytocinergic neurons that project to sacral spinal cord autonomic centers, modulating genital reflexes and central arousal pathways through descending neural circuits.

### Step 5: Metabolic & Appetite Modulation

MC3R and MC4R activation in arcuate nucleus neurons integrates with leptin-melanocortin signaling to modulate appetite-regulating neuropeptide expression, including suppression of orexigenic AgRP/NPY neurons and activation of anorexigenic POMC pathways.

## Researched Benefits

### Melanocortin-Mediated Pigmentation

Through MC1R activation and subsequent upregulation of melanogenic enzymes, Melanotan-2 stimulates eumelanin synthesis in epidermal melanocytes. Research demonstrates progressive skin darkening independent of UV exposure, mediated through the cAMP/PKA/CREB transcriptional pathway that governs melanin biosynthesis.

### Central Sexual Function Modulation

MC4R activation in hypothalamic and spinal cord autonomic centers modulates sexual arousal and erectile function through a central mechanism distinct from peripheral vasodilators. Clinical studies published in peer-reviewed urology journals have documented erectile responses in subjects following subcutaneous administration.

### Appetite and Energy Regulation

Melanocortin receptor signaling in hypothalamic feeding centers influences appetite regulation and energy expenditure through the leptin-melanocortin axis. Preclinical models demonstrate reduced food intake and altered body composition parameters during chronic administration protocols.

### Photoprotective Potential

Increased eumelanin content in the epidermis following Melanotan-2 administration may enhance the skin's intrinsic photoprotective capacity. Eumelanin absorbs ultraviolet radiation and scavenges free radicals, and research has explored melanocortin-stimulated pigmentation as a potential strategy for reducing UV-induced DNA damage.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | Initial loading phase of 0.25mg per day, gradually increasing to 0.5-1mg per day based on response and tolerability |
| Route | Subcutaneous injection |
| Duration | Loading phase of 2-4 weeks, followed by maintenance dosing at reduced frequency |
| Cycle Notes | Maintenance protocols typically reduce administration frequency to 1-2 times per week once desired response is achieved. Individual response varies significantly based on baseline skin type and melanocortin receptor polymorphisms. |
| Reconstitution | Reconstitute with bacteriostatic water. Using a 10mg vial with 2mL bacteriostatic water yields 5000mcg/mL concentration. Store reconstituted solution refrigerated at 2-8C and use within 28 days. |

> **Specialist note:** A your specialist will evaluate skin type, dermatological history, cardiovascular status, and current medications before initiating a Melanotan-2 protocol. Comprehensive dermatological screening including assessment of existing nevi is essential prior to administration. Regular monitoring during use is necessary given the compound's effects on melanocyte activity.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Lyophilized Powder |
| Amount | 10mg per vial |
| Purity | >99% |
| Purity Method | HPLC (High-Performance Liquid Chromatography) |
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 |
| Molecular Weight | 1024.18 g/mol |
| Storage | Store lyophilized powder at -20C. Reconstituted solution at 2-8C. Protect from light. |
| Appearance | White to off-white lyophilized powder |

## Medical Guidance

Melanotan-2 activates multiple melanocortin receptor subtypes simultaneously, influencing pigmentation, cardiovascular function, appetite, and central nervous system signaling. A thorough medical evaluation including dermatological screening, cardiovascular assessment, and review of current medications is essential before initiating any protocol. Individuals with a history of melanocytic nevi, cardiovascular conditions, or those taking antihypertensive medications require especially careful specialist assessment.

## Frequently Asked Questions

### What is Melanotan-2 and how does it differ from alpha-MSH?

Melanotan-2 is a synthetic cyclic heptapeptide analog of the naturally occurring alpha-melanocyte-stimulating hormone (alpha-MSH). Its cyclic structure makes it significantly more resistant to enzymatic degradation than linear alpha-MSH, resulting in a longer biological half-life and enhanced receptor binding potency. Unlike alpha-MSH, which is rapidly degraded in circulation, Melanotan-2 maintains pharmacological activity for a substantially longer duration following administration.

### What melanocortin receptors does Melanotan-2 activate?

Melanotan-2 acts as a non-selective agonist across the melanocortin receptor family (MC1R through MC5R). Its primary effects are mediated through MC1R activation in melanocytes, which drives eumelanin synthesis, and MC4R activation in hypothalamic neurons, which modulates sexual function and appetite signaling pathways. This non-selective profile distinguishes it from more targeted melanocortin analogs currently in clinical development.

### How is Melanotan-2 related to PT-141 (bremelanotide)?

PT-141 (bremelanotide) was developed directly from Melanotan-2 research as a more targeted melanocortin receptor agonist. While Melanotan-2 activates multiple receptor subtypes, PT-141 was optimized for preferential MC4R activity relevant to sexual function. PT-141 has received FDA approval for hypoactive sexual desire disorder in premenopausal women, representing the clinical translation of melanocortin research that originated with Melanotan-2 studies.

### Is medical supervision necessary for Melanotan-2 use?

Yes. Melanotan-2's non-selective receptor activation means it affects multiple physiological systems simultaneously, including pigmentation, cardiovascular function, appetite regulation, and central nervous system pathways. A specialist must evaluate individual risk factors including dermatological status, cardiovascular health, and medication interactions. Regular monitoring during administration is essential, particularly dermatological assessment of melanocytic nevi and moles.

### How should Melanotan-2 be stored and handled?

Store lyophilized Melanotan-2 at -20C protected from light and moisture. For reconstitution, slowly add bacteriostatic water along the vial wall to preserve peptide integrity. A 10mg vial reconstituted with 2mL bacteriostatic water yields 5000mcg/mL. Once reconstituted, store at 2-8C (standard refrigerator) and use within 28 days. Do not freeze reconstituted solution, and avoid repeated temperature cycling.

## Related Compounds

- /compounds/pt-141
- /compounds/kisspeptin
- /compounds/aod-9604